For instance, acitretin (Soriatane), an oral
systemic medication that has been on the market for more than a
decade, increased by 158 % between 2000 and 2008, while Humira — which is far more expensive to produce and newer, having received FDA approval for psoriasis in 2008 — has only increased 27 %
since 2003.